Consensus Bioventus Inc.

Equities

BVS

US09075A1088

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-08 pm EDT			5-day change	1st Jan Change
5.04 ^USD	-1.56%		+27.27%	-4.36%

May. 07	Bioventus Inc. Revises Earnings Guidance for the Full-Year 2024	CI
May. 07	Transcript : Bioventus Inc., Q1 2024 Earnings Call, May 07, 2024

Evolution of the average Target Price on Bioventus Inc.

Price target over the last 5 years

History of analyst recommendation changes

656f22b06.aHJGBtWXaYwJZIuhcolBQFVpQWLNR02Z3bHJAuC0M2A.PEIAMJjhNsJMBdjEOb0OCh8lIFSqKQnB6sKxeoLyBS8yGidfheUR4joPzg~19b2d970171636996e171420aba23963

Analyst Recommendations on Bioventus Inc.

Craig-Hallum Adjusts Price Target on Bioventus to $9 From $6, Maintains Buy Rating	Mar. 13	MT
Canaccord Genuity Upgrades Bioventus to Buy From Hold, Adjusts Price Target to $7 From $3.66	Dec. 07	MT
Craig-Hallum Adjusts Price Target on Bioventus to $5 From $10, Maintains Hold Rating	23-04-03	MT
Goldman Sachs Cuts Price Target on Bioventus to $2.50 From $13, Maintains Neutral Rating	22-11-30	MT
Craig-Hallum Downgrades Bioventus to Hold From Buy	22-11-22	MT
Morgan Stanley Adjusts Price Target on Bioventus to $5 From $11, Maintains Overweight Rating	22-11-10	MT
Canaccord Genuity Downgrades Bioventus to Hold From Buy, Adjusts Price Target to $6 From $18	22-11-09	MT
JPMorgan Downgrades Bioventus to Underweight From Overweight	22-11-09	MT
Morgan Stanley Adjusts Bioventus' Price Target to $11 From $12, Reiterates Overweight Rating	22-10-11	MT
Goldman Sachs Adjusts Bioventus' Price Target to $13 from $15, Maintains Neutral Rating	22-09-07	MT
Morgan Stanley Raises Bioventus' Price Target to $12 From $11, Maintains Overweight Rating	22-08-12	MT
Morgan Stanley Lowers Bioventus Price Target to $11 From $18, Maintains Overweight Rating	22-05-12	MT
Goldman Sachs Adjusts Bioventus Price Target to $17 From $19, Maintains Neutral Rating	22-03-21	MT
Craig-Hallum Starts Bioventus at Buy with $30 Price Target	22-03-15	MT
Morgan Stanley Resumes Bioventus at Overweight With $20 Price Target	21-11-15	MT
JPMorgan Reinstates Bioventus at Overweight With $25 Price Target	21-11-10	MT
BIOVENTUS : Goldman Sachs Cuts Bioventus to Neutral From Buy, Price Target to $19 From $20	21-07-01	MT
BIOVENTUS : Morgan Stanley Adjusts Price Target on Bioventus to $19 From $18, Maintains Overweight Rating	21-04-19	MT
BIOVENTUS : Morgan Stanley Starts Bioventus at Overweight With $18 Price Target	21-03-08	MT
BIOVENTUS : JPMorgan Initiates Bioventus at Overweight With $17 Price Target	21-03-08	MT
BIOVENTUS : Goldman Sachs Starts Bioventus at Buy With $19 Price Target	21-03-08	MT
BIOVENTUS : Canaccord Genuity Initiates Bioventus at Buy With $23 Price Target	21-03-08	MT